TrialCancer science2024

Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.

Masahiro Morise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.